Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  dalotuzumab
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-18 of 18 for your search:
Start Over
MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 to 120
Sponsor: Other
Protocol IDs: 2007-0910, NCI-2010-01049, NCT00769483
MK-0646, Etoposide, and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: Over 18
Sponsor: Other
Protocol IDs: I190, CAN-NCIC-IND190, CDR0000634447, IND190, NCT00869752
Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 07-162, NCT00610129
Study of Dalotuzumab (MK0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004 AM9)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 0646-004, 2007_529, NCT00614393
A Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (0646-007)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 0646-007, 2007_605, NCT00654420
MK-0646 Insulin Growth Factor 1 Receptor Antibody in Stage IIIb or IV Metastatic Non-Squamous Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 11386, MK-0646, NCT00799240
A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 8669-041, NCT01234857
A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 8669-064, NCT01605396
A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 0646-025, 2012-000317-36, NCT01609231
Infusion of MK0646 in Subjects With Advanced Solid Tumors (0646-002)(COMPLETED)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 0646-002, 2008_511, NCT00635778
Study of MK0646 in Patients With Solid Tumors (0646-009)(COMPLETED)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 0646-009, 2008_012, NCT00694356
Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 0646-008, 2008_518, CTRI/2009/091/000139, NCT00729742
A Combination Study With Ridaforolimus (MK8669) and Dalotuzumab (MK0646) in Patients With Advanced Cancer (8669-004)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 8669-004, 2008_538, NCT00730379
A Study of Dalotuzumab (MK0646) in Breast Cancer Patients (0646-013)
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: Over 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: 0646-013, MK0646-013, 2008_554, NCT00759785
Phase I Study of Dalotuzumab (MK0646) in Combination With Cetuximab and Irinotecan in Colorectal Cancer Patients (0646-016)
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 0646-016, 2009_602, NCT00925015
Phase I Dose Escalation Trial of MK0646 in Advanced Solid Tumors and Multiple Myeloma (0646-001)(COMPLETED)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 0646-001, 2007_660, NCT00701103
The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050)
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 8669-050, NCT01220570
Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 3 to 17
Sponsor: Pharmaceutical / Industry
Protocol IDs: 8669-062, NCT01431547
Start Over